Evommune, Inc. (NYSE:EVMN) Receives $38.60 Consensus Target Price from Analysts

Shares of Evommune, Inc. (NYSE:EVMN) have been assigned a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $39.1667.

A number of equities analysts have commented on the stock. Oppenheimer initiated coverage on shares of Evommune in a research note on Thursday. They set an “outperform” rating and a $42.00 target price on the stock. Wall Street Zen raised shares of Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. The Goldman Sachs Group upgraded Evommune to a “buy” rating in a report on Wednesday, January 7th. Morgan Stanley started coverage on Evommune in a research note on Monday, December 1st. They set an “overweight” rating and a $36.00 target price for the company. Finally, Evercore ISI assumed coverage on Evommune in a research note on Monday, December 1st. They issued an “outperform” rating and a $40.00 price target on the stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evommune stock. Capricorn Fund Managers Ltd acquired a new position in Evommune, Inc. (NYSE:EVMN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 60,000 shares of the company’s stock, valued at approximately $1,027,000. Capricorn Fund Managers Ltd owned about 0.19% of Evommune as of its most recent filing with the Securities and Exchange Commission.

Evommune Price Performance

NYSE EVMN opened at $18.75 on Tuesday. The stock’s fifty day moving average is $18.52. The firm has a market capitalization of $591 million and a price-to-earnings ratio of -2.32. Evommune has a fifty-two week low of $13.89 and a fifty-two week high of $24.03.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, December 11th. The company reported ($8.07) EPS for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The firm had revenue of $10.00 million during the quarter, compared to analyst estimates of $10.00 million.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.